UniQure's AMT-130 may slow Huntington's progression
The case argued for UniQure is that its gene therapy AMT-130, a one-time treatment delivered via brain surgery, has a reasonable basis to believe it may substantially slow the progression of Huntington's disease.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.